Charles Bailey, Ph.D.
Dr. Bailey is the former commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Dr. Bailey has 25 years' U.S. Army experience in R&D and management in infectious diseases and biological warfare defense. As an officer of the Defense Intelligence Agency, Dr. Bailey wrote extensively on foreign biological warfare capabilities. Dr. Bailey is currently the Executive Director for Research & International Relations at the National Center for Biodefense at George Mason University (GMU), and is a Distinguished Professor of Biology at GMU as well. The Acumen Journal of Life Sciences named Dr. Bailey as one of the top five biological warfare experts in the nation.
Dr. Alibek and Dr. Bailey, in addition to their national leadership roles at the NCBD, currently serve unpaid on Aethlon Medical's Science Advisory Board which they joined in the spring of 2004. It is possible that they may be compensated for future consulting work for the company. The Science Advisory Board is a group of globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries who provide scientific and medical guidance to the company's scientists.
Certain statements in this news release may be forward looking and involve risks and uncertainties. These include statements about the company's plans for testing and developing its technology and the potential future uses of the technology. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to raise capital when needed, the company's ability to complete the development of its planned products, the ability of the company to obtain FDA and other regulatory approvals permitting the sale of its products, the company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors as detailed in the company's Securities and Exchange Commission filings.
Aethlon Medical, Inc. is a featured Company on www.HomelandDefenseStocks.com and www.investorideas.com/Research/Industries/Biotech.asp